Pulse Biosciences (NASDAQ:PLSE – Get Free Report) issued its earnings results on Thursday. The company reported ($0.27) earnings per share (EPS) for the quarter, Zacks reports.
Pulse Biosciences Stock Performance
Shares of PLSE stock traded down $0.14 during mid-day trading on Thursday, hitting $15.66. 282,108 shares of the stock traded hands, compared to its average volume of 194,251. Pulse Biosciences has a 52-week low of $6.60 and a 52-week high of $25.00. The stock’s fifty day moving average is $18.87 and its two-hundred day moving average is $18.18.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
- Five stocks we like better than Pulse Biosciences
- How to Profit From Growth Investing
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Trading Halts Explained
- Top 3 Beverage Stocks Pouring Out Profits
- Quiet Period Expirations Explained
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
